Drug intelligence / Profile preview

SZ00407

Development stage: Unknown
Lead developer: Sarfez Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**SZ00407** is a Sarfez Pharmaceuticals investigational fixed-dose combination of a loop diuretic and a mineralocorticoid receptor antagonist for resistant hypertension, heart failure, and chronic kidney disease. Sarfez's pipeline identifies the program as an FDC Loop/MRA candidate in Phase 1; the individual active ingredients, molecular targets, dosage form, and route have not been publicly specified for the exact SZ00407 code. ([sarfez.com](https://www.sarfez.com/pipeline))

Beyond the preview

Go deeper on SZ00407.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SZ00407.

Explore the full profile